Breast cancer survival and hormone replacement therapy - A cohort analysis

Citation
Pj. Disaia et al., Breast cancer survival and hormone replacement therapy - A cohort analysis, AM J CL ONC, 23(6), 2000, pp. 541-545
Citations number
25
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Oncology
Journal title
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
ISSN journal
0277-3732 → ACNP
Volume
23
Issue
6
Year of publication
2000
Pages
541 - 545
Database
ISI
SICI code
0277-3732(200012)23:6<541:BCSAHR>2.0.ZU;2-I
Abstract
Controversy exists regarding the safety of hormone replacement therapy (HRT ) after a diagnosis of breast cancer. The objective of this study is to per form a matched cohort analysis to evaluate the impact of HRT on mortality i n breast cancer survivors. Patients with breast cancer who received HRT aft er diagnosis of breast cancer were identified. Control subjects were identi fied from the regional cancer registry. Matching criteria included age at d iagnosis, stage of breast cancer, and year of diagnosis. Controls were sele cted only if they were alive at the time of initiation of HRT of the matche d case. Only subjects not included in a previously reported matched analysi s were selected. One hundred twenty-five cases were matched with 362 contro ls. Ninety-eight percent (123/125) of the cases received systemic estrogen; 90/125 (72%) also received a progestational agent. The median interval bet ween diagnosis of breast cancer and initiation of HRT was 46 months (range 0-401 months). The median duration of HRT was 22 months (range 1-357 months ). The risk of death was lower among the HRT survivors; odds ratio 0.28 (95 % confidence interval 0.11-0.71). This analysis does not suggest that HRT a fter the treatment of breast cancer is associated with an adverse outcome.